<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38639670</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>23</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>23</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1477-2566</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Cytotherapy</Title><ISOAbbreviation>Cytotherapy</ISOAbbreviation></Journal><ArticleTitle>Adipose-derived stromal vascular fraction cells to treat long-term pulmonary sequelae of coronavirus disease 2019: 12-month follow-up.</ArticleTitle><Pagination><StartPage>1076</StartPage><EndPage>1083</EndPage><MedlinePgn>1076-1083</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.jcyt.2024.03.491</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1465-3249(24)00568-1</ELocationID><Abstract><AbstractText Label="BACKGROUND AIMS" NlmCategory="OBJECTIVE">Long coronavirus disease (COVID) is estimated to occur in up to 20% of patients with coronavirus disease 2019 (COVID-19) infections, with many having persistent pulmonary symptoms. Mesenchymal stromal cells (MSCs) have been shown to have powerful immunomodulatory and anti-fibrotic properties. Autologous adipose-derived (AD) stromal vascular fraction (SVF) contains MSC and other healing cell components and can be obtained by small-volume lipoaspiration and administered on the same day. This study was designed to study the safety of AD SVF infused intravenously to treat the pulmonary symptoms of long COVID.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Five subjects with persistent cough and dyspnea after hospitalization and subsequent discharge for COVID-19 pneumonia were treated with 40 million intravenous autologous AD SVF cells and followed for 12 months, to include with pulmonary function tests and computed tomography scans of the lung.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">SVF infusion was safe, with no significant adverse events related to the infusion out to 12 months. Four subjects had improvements in pulmonary symptoms, pulmonary function tests, and computed tomography scans, with some improvement noted as soon as 1 month after SVF treatment.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">It is not possible to distinguish between naturally occurring improvement or improvement caused by SVF treatment in this small, uncontrolled study. However, the results support further study of autologous AD SVF as a treatment for long COVID.</AbstractText><CopyrightInformation>Copyright &#xa9; 2024 International Society for Cell &amp; Gene Therapy. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Carstens</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Surgery, Hospital Escuela Oscar Danilo Rosale Arg&#xfc;ello, Le&#xf3;n, Nicaragua; Wake Forest Institute for Regenerative Medicine, Winston-Salem, North Carolina, USA. Electronic address: MichaelCarstens@mac.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Trujillo</LastName><ForeName>Jessy</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Medicine, Hospital Monte Espa&#xf1;a, Managua, Nicaragua.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dolmus</LastName><ForeName>Yanury</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Pediatrics, Hospital Escuela Cesar Amador Molina, Matagalpa, Nicaragua.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rivera</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Radiology, Hospital Escuela Cesar Amador Molina, Matagalpa, Nicaragua.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calderwood</LastName><ForeName>Santos</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Surgery, Hospital Escuela Cesar Amador Molina, Matagalpa, Nicaragua.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lejarza</LastName><ForeName>Judith</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Surgery, Hospital Escuela Oscar Danilo Rosale Arg&#xfc;ello, Le&#xf3;n, Nicaragua.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf3;pez</LastName><ForeName>Carlos</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Medicine, Hospital Escuela Oscar Danilo Rosales Arg&#xfc;ello, Le&#xf3;n, Nicaragua.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bertram</LastName><ForeName>Kenneth</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Wake Forest Institute for Regenerative Medicine, Winston-Salem, North Carolina, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>04</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Cytotherapy</MedlineTA><NlmUniqueID>100895309</NlmUniqueID><ISSNLinking>1465-3249</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="N">therapy</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D045164" MajorTopicYN="Y">Mesenchymal Stem Cell Transplantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059630" MajorTopicYN="Y">Mesenchymal Stem Cells</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000273" MajorTopicYN="Y">Adipose Tissue</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008168" MajorTopicYN="Y">Lung</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000000981" MajorTopicYN="N">diagnostic imaging</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012129" MajorTopicYN="N">Respiratory Function Tests</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014182" MajorTopicYN="N">Transplantation, Autologous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014057" MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">DLCO</Keyword><Keyword MajorTopicYN="N">adipose-derived mesenchymal cells</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">pulmonary fibrosis</Keyword><Keyword MajorTopicYN="N">stromal vascular fraction</Keyword></KeywordList><CoiStatement>Declaration of Competing Interest MC is a consultant for GID Bio. All other authors have no commercial, proprietary, or financial interest in the products or companies described in this article .</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>6</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>3</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>3</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>24</Day><Hour>16</Hour><Minute>41</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>4</Month><Day>19</Day><Hour>12</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>4</Month><Day>19</Day><Hour>10</Hour><Minute>31</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38639670</ArticleId><ArticleId IdType="doi">10.1016/j.jcyt.2024.03.491</ArticleId><ArticleId IdType="pii">S1465-3249(24)00568-1</ArticleId></ArticleIdList></PubmedData></PubmedArticle></PubmedArticleSet>